Shake it Up Australia Foundation

Last updated
The Shake It Up Australia Foundation
AbbreviationSIUAF
Formation2011;13 years ago (2011)
Founders
  • Clyde Campbell
  • Greg Campbell
Type Non-for-profit organisation
PurposePromote and fund Parkinson's research
Area served
Australia
MethodDonations, grants
Key people
  • Clyde Campbell (chairman)
  • Graeme Fear (vice chairman)
Website shakeitup.org.au

The Shake It Up Australia Foundation (SIUAF) is an Australian non-for-profit foundation founded in 2011 by Clyde and Greg Campbell. [1] It is partnered with the Michael J. Fox Foundation (MJFF) to achieve the foundations primary aims of "promoting and funding Parkinson's disease research in Australia to slow, stop and cure the disease". [2] [3] Together MJFF and SIUAF are the largest non-government funders of Parkinson's research across multiple institutes in Australia. [4] Since its founding, the foundation has co-founded 38 Parkinson's research projects across 12 institutes to the value of over $10.8 million. [3] The foundation's funding model ensures that 100% of proceeds goes towards Parkinson's research in Australia. This is possible due to the founding directors covering all overhead costs and expenses. In January 2019, Shake It Up are one of the partner organisation in the Australian Parkinson's Mission which was awarded a $30 million-dollar grant to test repurposed drugs in clinical trials. [5]

Contents

Parkinson's disease

Parkinson's disease is a common neurological disease affecting 10 million people worldwide, with 38 Australian's being diagnosed each day. [6] The disease is characterised by the loss of dopamine producing cells accompanied with chronic inflammation within the brain. [7] It is caused by the loss of cells in various areas of the brain, significantly within the substantia nigia. [8] Patients with Parkinson's, the loss dopamine producing neurons cause high levels of neuroinflamation to occur, mostly affecting the substantia nigra. [9] When dopamine levels are depleted, the motor system nerves are unable to control movement and coordination. Over time, the dopamine producing cells are lost and motor type symptoms occur. People live with Parkinson's for a substantial amount of time before diagnosis when 80% of the dopamine producing cells are already lost. [10] Currently there is no definitive test to diagnose Parkinson's but current clinical trials are showing promising results into ways to identify biomarkers that will detect the disease by a simple blood test at an earlier stage. [11]

Signs and symptoms

The most recognisable symptoms are "motor related" however non-motor symptoms can consist of autonomic dysfunction, sleep difficulties, sensory such as altered sense of smell and neuropsychiatric problems (mood, cognition, behaviour or thought alterations). [12]

Four motor symptoms are considered the primary sign by which a diagnosis for Parkinson's is made upon; Tremor, Slowness of movement (bradykinesia), postural instability and rigidity. [12] The most common presenting symptoms of Parkinson's within patients is a slow coarse tremor which disappears during voluntary movement and in the deeper stages of sleep. [12] It typically appears in one hand and affects both hands are the disease progresses. [12]

About Clyde

Clyde Campbell with wife Carolyn and three kids Josh (20), Zoe (18) and Phoebe (14) Family-Shot-2015-1024x623.jpg
Clyde Campbell with wife Carolyn and three kids Josh (20), Zoe (18) and Phoebe (14)

Originally, from Northern New South Wales, Clyde lives in Northern Sydney with wife Carolyn and three kids Josh (20), Zoe (18) and Phoebe (14). [13] Starting out Clyde was an electrical apprentice in NSW, which lead to him forming his own company in 1987, Machinery Automation and Robotics. [14] This company grew to 70 staff which servicing Australian and International clients with high tech automation and robotic solutions. [14] He had a vision for technology as a solution for problems and had a goal of making a difference to individual's lives.

Clyde in 2009, was diagnosed with Parkinson's disease after noticing a tremor in his left hand when holding notes at a company meeting. [15] Clyde's faced the hardship of coming to terms with having an incurable disease that deteriorates progressively over time. [15] After coming to terms with his prognosis, Clyde set out to learn as much about Parkinson's disease and what was being done in the worldwide effort to find a cure. This ensured his goal of finding a cure for Parkinson's.

He found that despite the multitude of foundations supporting Parkinson's research and Australia having some of the World's leading scientist's specialising in Parkinson's research, they required financial assistance to accelerate the research on a global scale. [13] This launched the Shake It Up Australia Foundation to increase awareness in Australia and increase funding to Australian institutions to find a cure. His vision in establishing the foundation was to "create an opportunity for everyone in Australia to make a difference". [16]

Funding model

Shake it Up's funding model revolves around 100% of proceeds going towards funding research to cure Parkinson's disease, with the founders Clyde and Greg Campbell covering all overhead cost and expenses of the foundation. [17] It was a decision made by the awareness of the limited resources available in a competitive market and the need for funds allocated to non-for-profit and social sector to be managed efficiently to accelerate the path to a cure. [17] It has funded over $10.8 million into Australian institutions for research. [3]

Government funding

In January 2019, the NSW federal government awarded a $36.8 million-dollar grant for Parkinson's medical research through the Australian Parkinson's Mission and Parkinson's nurses to help improve the lives of those diagnosed and find a way to slow, stop and cure the debilitating disease. [5] This was achieved by the Australian Parkinson's Mission initiative, an international collaboration developed by the Garvan Institute of Medical Research, Shake It Up Australia Foundation, Parkinson's Australia, The Cure Parkinson's Trust and The Michael J. Fox Foundation for Parkinson's Research. [18] It is an innovative research project combining clinical trials with genomics research for people with Parkinson's. [18]

30 million dollars of the grant will be used to test repurposed drugs in a world's first in a Parkinson's clinical trial design by the Australian Parkinson's Mission, to identify effective safe treatments and fast track them to patients. Associate Professor Antony Cooper of the Garvan Institute of Medical Research will lead the research program. [19] The mission will sequence the genome of each patient, to identify the unknown causes, discover biomarkers and determine whether there are Parkinsons's subtypes that can be targeted with specific drugs. [20] Head of the Neurodegeneration and Neurogenomics Program at the Garvan Institute, said that the mission would be the "first step towards personalised medicine for Parkinson's patients" and further drug discovery. [20] Its first clinical trial will assign 300 patients to randomly receive medication for existing conditions. [20]

The further 6.8 was given to Primary Health Networks over the next four years from 2019, to ease access to specialist nurses in the community for people with movement disorders including Parkinson's disease. [5]

Partnership with The Michael J. Fox Foundation

Michael J. Fox (Diagnosed with Parkinson's at age 29, in 1991) Michael J. Fox 2012 (cropped).jpg
Michael J. Fox (Diagnosed with Parkinson's at age 29, in 1991)

Clyde's goal of finding a cure for Parkinson's led him to the Michael J. Fox Foundation for Parkinson's Research in the USA and the work they do to fund medical research targeted at finding better treatments, and a cure. [16] In 2011, the Shake It Up Australia Foundation established a collaboration with the Michael J. Fox Foundation. [16] This leveraged MJFF's Parkinson's drug development to Australia.

The Michael J. Fox Foundation was founded in 2000 by actor Michael J Fox, funding more than $800 million in research to date. [21] MJFF approach of assessing, funding and project managing research globally eliminates redundancy, ensures efficiency and unites the global community to find a cure. [2] This collaboration builds a strong foundation for promising research. The partnership allows the Shake it Up Foundation to be internationally competitive and strategically managed. [22] It allows both parties to maximise capital raised from the Australian Parkinson's community to accelerate better research and treatments to slow, stop and cure the disease. [2]

Research projects

SIUAF and MJFF fund strategic, non-redundant and internationally competitive research projects. They have funded 38 research projects, within 12 different institutions since starting out in 2011. All research projects are assessed and validated by a panel of expert scientists at the Michael J. Fox Foundation to eliminate redundancy globally. [23] Once the projects are approved, they are monitored and benchmarked by a team of PhD's and business trained project managers. [23] Listed below are research projects that have been funded or are currently being funded by the Shake It Up Australia Foundation which have shown positive outcomes to slow, stop and cure Parkinson's disease:

Professor Andrew Hill and Lesley Chang at La Trobe University Andrew-hill.jpg
Professor Andrew Hill and Lesley Chang at La Trobe University

Biomarker's research at La Trobe University

Shake it Up committed funding to Professor Andrew Hill and Dr Lesley Cheng at La Trobe University to test the power of extracellular vesicles or cell particles, to detect Parkinson's via a simple blood test. [24] The biological clue the test is looking for relates to the bloods 'appetite' for blood, as patient's with Parkinson's disease have white blood cells which consumes oxygen four times faster than normal cells. [25] They are assessing whether this biomarker can be collected to determine a patient's neurological status. [25] Researchers used blood samples from The Australian Parkinson's Disease Registry to determine whether biomarkers could be detected in both early onset and advanced patients who have taken medication for upwards of 5 years. [25] Human trials of this test, which picks up on a key biological biomarker found in the blood of Parkinson's patients, delivered a 95% accuracy rate. [11]

La Trobe's development of the world's-first diagnostic blood test is labelled by Parkinson's patients and scientists as a "medical breakthrough" in the SMH. [26] Professor Fisher stated that the test's early diagnosis and treatment abilities will provide "better outcomes and a greater quality of life for people with the condition". [11] A definitive diagnostic test will enable early intervention, limiting the number of brain cells and dopamine levels lost before one's diagnosis. La Trobe's research team estimates that the diagnostic blood test could be available within the next five years if additional funding is provided to speed up the development of the trial. [27]

Inflammation study at the University of Queensland

The NLRP3 inflammasome (green) is expressed by immune cells (red) in the brains of people with Parkinson's disease. MED Parkinsons 181029small.jpg
The NLRP3 inflammasome (green) is expressed by immune cells (red) in the brains of people with Parkinson's disease.

The inflammasome study conducted at the University of Queensland produced a promising new therapy to stop Parkinson's disease progressing through counteracting brain inflammation caused by immune cells. [28] The study primarily targeting ways to counteract immune cells, specifically the microglia which is highly activated in patients with Parkinson's disease by NLRP3 inflammasome. The NLRP3 inflammasome reacts to synuclein containing protein clumps by increasing inflammatory signals which contributes to the depletion of dopamine producing cells within the brain. [29] Whilst, recruiting more pathological proteins to create an intense cycle of neuroinflammation and a synuclein buildup within the brain. [29] The study found that a small molecule MCC950 administered orally once a day, stopped the development of Parkinson's disease in several animal models. [30] It was found to block NLRP3 activation within the brain and prevent both the loss of dopamine producing brain cells and neuroinflammation, resulting in significantly improved motor function - the leading symptom of parkinson's disease. [30] UQ Bioscience researcher Professor Matt Cooper stated that the "MCC950 molecule effectively 'cooled the brains on fire', turning down microglial inflammatory activity, and allowing neurons to function normally." [31]

Currently, there are no medications on the market that prevent brain cell loss in Parkinson's patients. Current therapies focus on managing symptoms rather than halting the progression of the degenerative disease. [31] The promising results from this study validate a promising new target for Parkinson's researcher's and therapeutics to substantiate a potential drug to stop the progression of Parkinson's disease. [32] The drug is now being commercialised for clinical trials by inflamzone, [31] a pioneering biotech company that develops several small molecule drugs that inhibit harmful inflammation within the brain. [33] With the success and extensive research studies taken place to ensure the drug is safe, tolerable and efficacious, human trials of the drug is now attainable. [34] Phase 1 of the clinical trials on healthy volunteers is expected to start in 2019, with phase 2 trials on Parkinson's patient's predicted to take place in 2020 dependent on the results of Phase 1. [31]

Related Research Articles

<span class="mw-page-title-main">MPTP</span> Chemical compound

MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) is an organic compound. It is classified as a tetrahydropyridine. It is of interest as a precursor to the neurotoxin MPP+, which causes permanent symptoms of Parkinson's disease by destroying dopaminergic neurons in the substantia nigra of the brain. It has been used to study disease models in various animals.

Neuropharmacology is the study of how drugs affect function in the nervous system, and the neural mechanisms through which they influence behavior. There are two main branches of neuropharmacology: behavioral and molecular. Behavioral neuropharmacology focuses on the study of how drugs affect human behavior (neuropsychopharmacology), including the study of how drug dependence and addiction affect the human brain. Molecular neuropharmacology involves the study of neurons and their neurochemical interactions, with the overall goal of developing drugs that have beneficial effects on neurological function. Both of these fields are closely connected, since both are concerned with the interactions of neurotransmitters, neuropeptides, neurohormones, neuromodulators, enzymes, second messengers, co-transporters, ion channels, and receptor proteins in the central and peripheral nervous systems. Studying these interactions, researchers are developing drugs to treat many different neurological disorders, including pain, neurodegenerative diseases such as Parkinson's disease and Alzheimer's disease, psychological disorders, addiction, and many others.

<span class="mw-page-title-main">Apomorphine</span> Chemical compound

Apomorphine, sold under the brand name Apokyn among others, is a type of aporphine having activity as a non-selective dopamine agonist which activates both D2-like and, to a much lesser extent, D1-like receptors. It also acts as an antagonist of 5-HT2 and α-adrenergic receptors with high affinity. The compound is historically a morphine decomposition product made by boiling morphine with concentrated acid, hence the -morphine suffix. Contrary to its name, apomorphine does not actually contain morphine or its skeleton, nor does it bind to opioid receptors. The apo- prefix relates to it being a morphine derivative ("[comes] from morphine").

In the management of Parkinson's disease, due to the chronic nature of Parkinson's disease (PD), a broad-based program is needed that includes patient and family education, support-group services, general wellness maintenance, exercise, and nutrition. At present, no cure for the disease is known, but medications or surgery can provide relief from the symptoms.

<span class="mw-page-title-main">NLRP3</span> Human protein and coding gene

NLR family pyrin domain containing 3 (NLRP3), is a protein that in humans is encoded by the NLRP3 gene located on the long arm of chromosome 1.

MPP<sup>+</sup> Chemical compound

MPP+ (1-methyl-4-phenylpyridinium) is a positively charged organic molecule with the chemical formula C12H12N+. It is a neurotoxin that acts by interfering with oxidative phosphorylation in mitochondria by inhibiting complex I, leading to the depletion of ATP and eventual cell death.

<span class="mw-page-title-main">Parkinson's disease</span> Long-term degenerative neurological disorder

Parkinson's disease (PD), or simply Parkinson's, is a chronic degenerative disorder of the central nervous system that affects both the motor system and non-motor systems. The symptoms usually emerge slowly, and as the disease progresses, non-motor symptoms become more common. Early symptoms are tremor, rigidity, slowness of movement, and difficulty with walking. Problems may also arise with cognition, behaviour, sleep, and sensory systems. Parkinson's disease dementia is common in advanced stages.

<span class="mw-page-title-main">Befiradol</span> Chemical compound

Befiradol is an experimental drug being studied for the treatment of levodopa-induced dyskinesia. It is a potent and selective 5-HT1A receptor full agonist.

The research in Parkinson's disease refers to any study intended to help answer questions about etiology, diagnostic approaches or new treatments of Parkinson's disease (PD) by studying their effects on human subjects. Clinical trials are designed and conducted by scientists and medical experts, who invite participants to undergo testing new vaccines, therapies, or treatments.

<span class="mw-page-title-main">Clinical neurochemistry</span>

Clinical neurochemistry is the field of neurological biochemistry which relates biochemical phenomena to clinical symptomatic manifestations in humans. While neurochemistry is mostly associated with the effects of neurotransmitters and similarly functioning chemicals on neurons themselves, clinical neurochemistry relates these phenomena to system-wide symptoms. Clinical neurochemistry is related to neurogenesis, neuromodulation, neuroplasticity, neuroendocrinology, and neuroimmunology in the context of associating neurological findings at both lower and higher level organismal functions.

Parkinson's disease is the 2nd most prevalent neurological disorder within the United States and Europe, affecting around 1% of the population over the age of 60. While the link connecting the onset of Parkinson's disease to environmental factors is known, the link between dietary patterns and the disease is just beginning to be researched more fully. Additionally, other research has sought to examine the symptoms of the disease and propose methods on how to alleviate these symptoms through changes in diet. Current medications that work to alleviate the symptoms of Parkinson's disease can also be made more effective through changes in diet.

Gene therapy in Parkinson's disease consists of the creation of new cells that produce a specific neurotransmitter (dopamine), protect the neural system, or the modification of genes that are related to the disease. Then these cells are transplanted to a patient with the disease. There are different kinds of treatments that focus on reducing the symptoms of the disease but currently there is no cure.

Lorenz Studer is a Swiss biologist. He is the founder and director of the Center for Stem Cell Biology at Memorial-Sloan Kettering Cancer Center in New York City. He is a developmental biologist and neuroscientist who is pioneering the generation of midbrain dopamine neurons for transplantation and clinical applications. His expertise in cell engineering spans a wide range of cells/tissues within the nervous system geared toward disease modeling and exploring cell replacement therapy. Currently, he is a member of the Developmental Biology Program and Department of Neurosurgery at Memorial Sloan-Kettering Cancer Center and a Professor of Neuroscience at Weill Cornell Medical College in New York City, NY.

<span class="mw-page-title-main">Giovanna Mallucci</span> British neuroscientist

Giovanna Rachele Mallucci is van Geest Professor of Clinical Neurosciences at the University of Cambridge in England and associate director of the UK Dementia Research Institute at the University of Cambridge. She is a specialist in neurodegenerative diseases.

Katharina Sophia Volz is a medical researcher and entrepreneur. She is the founder and chief executive officer of OccamzRazor, a biotechnology start-up based in New York City and San Francisco. OccamzRazor uses machine learning to discover and develop drugs for brain diseases.

Tom Isaacs was a British charity fundraiser and the President of The Cure Parkinson's Trust, which he co-founded. Among other achievements, he completed a 4,500-mile charity walk around the coast of Britain in order to raise funds for research into Parkinson's disease

Dopamine transporter deficiency syndrome (DTDS), also known as infantile parkinsonism-dystonia, is a rare movement disorder that causes progressively worsening dystonia and parkinsonism. It is the first known inherited dopamine 'transportophathy.'

<span class="mw-page-title-main">2020 California Proposition 14</span> Citizen-initiated ballot measure

California Proposition 14 is a citizen-initiated ballot measure that appeared on the ballot in the 2020 California elections, for November 3, 2020. It authorizes state bonds to be issued worth $5.5 billion, which will fund the California Institute for Regenerative Medicine (CIRM), which serves as the state's center for stem cell research, and enable it to continue its operations. This measure passed with 51% of the vote.

<span class="mw-page-title-main">Dapansutrile</span> Chemical compound

Dapansutrile (OLT1177) is an inhibitor of the NLRP3 inflammasome.

<span class="mw-page-title-main">Alzheimer's disease and COVID-19</span>

Studies have shown that Alzheimer's disease (AD) patients are at an increased risk of morbidity and mortality from SARS-CoV-2, the virus that causes COVID-19. AD is the most common cause of dementia worldwide and is clinically defined by amyloid beta plaques, neurofibrillary tangles, and activation of the brain's immune system. While COVID-19 has been known to more severely impact elderly populations, AD patients have been shown to have a higher rate of SARS-CoV-2 infection compared to cognitively normal patients. The disproportionate risk of COVID-19 in AD patients is thought to arise from an interplay of biological and social factors between the two diseases. Many common biological pathways are shared between COVID-19 and AD, notably those involved in inflammation. Genetic factors that put individuals at risk for AD, such as the APOE4 genotype, are associated with worse outcomes during SARS-CoV-2 infection. Cognitive impairment in AD may prevent patients from following proper public health guidelines, such as masking and social distancing, increasing their risk of infection. Additionally, studies have shown cognitively normal COVID-19 patients are at an increased risk of AD diagnosis following recovery, suggesting that COVID-19 has the potential to cause AD.

References

  1. ↑ "SHAKE IT UP AUSTRALIA FOUNDATION - 2018 Insight". 2019 INSIGHT Into PD UNITES!. Retrieved 2019-06-11.
  2. 1 2 3 "Michael J. Fox Foundation Announces Collaboration with Shake It Up Foundation Australia". The Michael J. Fox Foundation for Parkinson's Research | Parkinson's Disease. 13 August 2011. Retrieved 2019-06-11.
  3. 1 2 3 "About Shake It Up Australia Foundation - Parkinson's Research". Shake It Up Australia Foundation. Retrieved 2019-06-11.
  4. ↑ "World Parkinson's Day | The search for a cure continues". 2GB. 10 April 2019. Retrieved 2019-06-11.
  5. 1 2 3 Health, Australian Government Department of (2019-05-16). "Ministers". Australian Government Department of Health. Retrieved 2019-06-08.
  6. ↑ "Living with Parkinson's Disease | Deloitte Australia | Deloitte Access Economics report, Health". Deloitte Australia. Retrieved 2019-05-28.
  7. ↑ Rocha, Natália Pessoa; de Miranda, Aline Silva; Teixeira, Antônio Lúcio (2015). "Insights into Neuroinflammation in Parkinson's Disease: From Biomarkers to Anti-Inflammatory Based Therapies". BioMed Research International. 2015: 628192. doi: 10.1155/2015/628192 . ISSN   2314-6133. PMC   4532803 . PMID   26295044.
  8. ↑ Port, Dr Beckie (2019-02-21). "What brain areas are affected by Parkinson's?". Medium. Retrieved 2019-06-07.
  9. ↑ Havrda, Matthew C.; Hickey, William F.; Lee, Stephen L.; Wilkins, Owen M.; Christensen, Brock C.; Feldman, Mary S.; Howard, Joseph M.; Young, Alison L.; Martinez, Eileen M. (2018-08-15). "NLRP3 expression in mesencephalic neurons and characterization of a rare NLRP3 polymorphism associated with decreased risk of Parkinson's disease". npj Parkinson's Disease. 4 (1): 24. doi:10.1038/s41531-018-0061-5. ISSN   2373-8057. PMC   6093937 . PMID   30131971.
  10. ↑ DeMaagd, George; Philip, Ashok (2015). "Parkinson's Disease and Its Management". Pharmacy and Therapeutics. 40 (8): 504–532. ISSN   1052-1372. PMC   4517533 . PMID   26236139.
  11. 1 2 3 University, La Trobe. "World-first blood test for Parkinson". www.latrobe.edu.au. Retrieved 2019-06-06.
  12. 1 2 3 4 Jankovic, J (2008-04-01). "Parkinson's disease: clinical features and diagnosis". Journal of Neurology, Neurosurgery & Psychiatry. 79 (4): 368–376. doi: 10.1136/jnnp.2007.131045 . ISSN   0022-3050. PMID   18344392.
  13. 1 2 "Clyde Campbell - Founder Shake It Up Australia Foundation shares his PD Story". Shake It Up Australia Foundation. 2011-09-23. Retrieved 2019-06-11.
  14. 1 2 Automation, Machinery (2015-02-16). "Machinery Automation & Robotics (MAR) has been acquired by Scott Technology". Manufacturers' Monthly. Retrieved 2019-06-11.
  15. 1 2 Attitude (2018-08-18), Living with Parkinson's: Clyde , retrieved 2019-06-11
  16. 1 2 3 "Sunday Night Program with Michael J. Fox and Clyde Campbell | Shake It Up Foundation". Shake It Up Australia Foundation. 2012-03-14. Retrieved 2019-06-11.
  17. 1 2 "Our Research Funding Model". Shake It Up Australia Foundation. Retrieved 2019-06-08.
  18. 1 2 "About the program | Australian Parkinson's Mission". Garvan Institute of Medical Research. Retrieved 2019-06-08.
  19. ↑ "$30 million grant for Parkinson's medical research". Parkinson's NSW. Retrieved 2019-06-11.
  20. 1 2 3 "Australian Parkinson's Mission integrates breakthrough genomics and clinical trials | Garvan Institute of Medical Research" . Retrieved 2019-06-11.
  21. ↑ Saval, Malina (2018-08-08). "Michael J. Fox on Parkinson's, Overcoming Fear and the Race for a Cure". Variety. Retrieved 2019-06-11.
  22. ↑ "Shake It Up Australia partners with The Michael J. Fox Foundation for Parkinson's Research". Shake It Up Australia Foundation. Retrieved 2019-06-11.
  23. 1 2 "SHAKE IT UP AUSTRALIA FOUNDATION - 2018 Insight". 2019 INSIGHT Into PD UNITES!. Retrieved 2019-06-11.
  24. ↑ "Parkinson's Research Project Funded at La Trobe University". Shake It Up Australia Foundation. 2019-04-15. Retrieved 2019-06-08.
  25. 1 2 3 University, La Trobe. "Diagnosing Parkinson's disease". www.latrobe.edu.au. Retrieved 2019-06-06.
  26. ↑ Smith, Bridie (2016-04-19). "Breakthrough Parkinson's disease blood test". The Sydney Morning Herald. Retrieved 2019-06-06.
  27. ↑ "Diagnostic blood test shows promise in early detection of Parkinson's". newatlas.com. 2 May 2016. Retrieved 2019-06-06.
  28. ↑ "Researchers may stop Parkinson's by 'cooling off' brain". Medical News Today. 2 November 2018. Retrieved 2019-06-08.
  29. 1 2 Dolgin, Elie (2019-01-21). "Parkinson's drug makers target inflammasome". Nature Biotechnology. doi:10.1038/d41587-019-00005-8. S2CID   92481206.
  30. 1 2 Woodruff, Trent M.; Cooper, Matthew A.; Schroder, Kate; Kanthasamy, Anumantha G.; O’Neill, Luke A.; Rowe, Dominic B.; Butler, Mark S.; Robertson, Avril A. B.; Mantovani, Susanna (2018-10-31). "Inflammasome inhibition prevents α-synuclein pathology and dopaminergic neurodegeneration in mice". Science Translational Medicine. 10 (465): eaah4066. doi:10.1126/scitranslmed.aah4066. ISSN   1946-6234. PMC   6483075 . PMID   30381407.
  31. 1 2 3 4 Queensl, The University of; Lucia, Australia Brisbane St; Gatton, QLD 4072 +61 7 3365 1111 Other Campuses: UQ; Maps, UQ Herston; Queensl, Directions © 2019 The University of. "Cooling 'brains on fire' to treat Parkinson's". UQ News. Retrieved 2019-06-08.{{cite web}}: CS1 maint: numeric names: authors list (link)
  32. ↑ "Validation of a new target in Parkinson's Disease". Inflazome. Retrieved 2019-06-08.
  33. ↑ "Science". Inflazome. Retrieved 2019-06-08.
  34. ↑ Andrew Koemeter-Cox, PhD Associate Director Research Programs (30 January 2019). "Inflammation: Our Brain's Friend and Foe". The Michael J. Fox Foundation for Parkinson's Research | Parkinson's Disease. Retrieved 2019-06-08.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.